AES Corp vs IDEXX Laboratories, Inc. — how do they compare? AES Corp trades at $14.72 (market cap $10.49B), while IDEXX Laboratories, Inc. trades at $571.39 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 4.4× AES Corp's market cap, and AES Corp pays a 4.79% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| AES | IDXX | |
|---|---|---|
Market Cap | $10.49B | $46.22B |
Sector | Utilities | Health |
52-Week High | $17.28 | $766.68 |
52-Week Low | $12.51 | $526.44 |
Enterprise Value | $40.75B | $47.12B |
Dividend Yield | 4.79% | — |
Signals from Pluang's Aura AI — not financial advice
AES trades at $14.73, down slightly by 0.03%, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong profitability with a 14.34% net income margin and 45.05% ROE, supported by recent earnings beats. A pending $33.4 billion acquisition by a consortium led by Global Infrastructure Partners and EQT, approved by stockholders in June 2026, dominates recent news, alongside a quarterly dividend of $0.18 per share.
The outlook is heavily influenced by the acquisition, offering a near-term upside to the $15 buyout price, but regulatory and shareholder approval risks remain. Long-term fundamentals are solid with projected revenue growth to $13.1 billion in 2026, though high debt levels and integration challenges post-acquisition pose risks. Analyst sentiment is mixed with a buy consensus of 43%.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Trailing returns across standard periods
Latest headlines on both assets
AES is a global power company operating across 14 countries and 4 continents. Its current generation portfolio as of year-end 2021 consists of over 31 gigawatts of generation, with the generation mix composed of renewables (43%), gas (32%), coal (23%), and oil (2%). The company has 3.5 gigawatts of generation under construction. AES has majority ownership and operates six electric utilities distributing power to 2.6 million customers.
Read more on AES →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →